Compare Stocks

→ top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$2.71 +1.1%	$2.75	$1.62 ▼ $4.05	$69.46M	-1	5,392 shs	794 shs
ANVS Annovis Bio	$11.91 +3.6%	$10.39	$5.42 ▼ $22.49	$131.07M	1.59	265,365 shs	226,539 shs
GLS Gelesis		$0.21	$0.11 ▼ $5.71	$11.63M	0.88	386,034 shs	185,100 shs
RPHM Reneo Pharmaceuticals	$1.68 -0.6%	$1.66	$0.98 ▼ $10.98	$55.98M	0.24	276,695 shs	78,044 shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	+2.26%	-8.45%	+8.40%	+11.98%	-2.17%
ANVS Annovis Bio	+3.61%	+18.93%	+5.26%	+30.97%	-19.62%
GLS Gelesis	0.00%	0.00%	0.00%	0.00%	0.00%
RPHM Reneo Pharmaceuticals	-0.89%	+1.52%	+0.90%	+1.52%	-82.70%

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	1.0899 of 5 stars	3.5	3.0	0.0	0.0	0.0	1.7	0.0
ANVS Annovis Bio	1.1284 of 5 stars	3.4	1.0	0.0	0.0	1.2	1.7	0.6
GLS Gelesis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RPHM Reneo Pharmaceuticals	0.8952 of 5 stars	2.9	0.0	0.0	0.0	0.6	2.5	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	3.00	Buy	$6.67	146.00% Upside
ANVS Annovis Bio	2.75	Moderate Buy	$27.75	133.10% Upside
GLS Gelesis	N/A	N/A	N/A	N/A
RPHM Reneo Pharmaceuticals	1.88	Reduce	$18.14	982.84% Upside

Current Analyst Ratings

Latest ANVS, RPHM, ANEB, and GLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
3/21/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
2/28/2024	ANVS Annovis Bio	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$9.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.41 per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	($0.73) per share	N/A
GLS Gelesis	$25.77M	0.00	N/A	N/A	($0.34) per share	0.00
RPHM Reneo Pharmaceuticals	N/A	N/A	N/A	N/A	$2.66 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$11.73M	-$0.42	N/A	N/A	N/A	N/A	-109.40%	-98.40%	5/9/2024 (Estimated)
ANVS Annovis Bio	-$56.20M	-$6.22	N/A	N/A	N/A	N/A	-446.06%	-257.97%	5/9/2024 (Estimated)
GLS Gelesis	-$56.03M	-$1.40	N/A	N/A	N/A	-221.38%	N/A	-14.98%	N/A
RPHM Reneo Pharmaceuticals	-$77.39M	-$2.52	N/A	N/A	N/A	N/A	-73.14%	-63.85%	5/9/2024 (Estimated)

Latest ANVS, RPHM, ANEB, and GLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/28/2024	Q4 2023	RPHM Reneo Pharmaceuticals	-$0.55	-$0.70	-$0.15	-$0.70	N/A	N/A
2/13/2024	Q2 2024	ANEB Anebulo Pharmaceuticals	-$0.11	-$0.11	N/A	-$0.11	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
GLS Gelesis	N/A	N/A	N/A	N/A	N/A
RPHM Reneo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	6.72	6.72
ANVS Annovis Bio	N/A	2.39	2.39
GLS Gelesis	N/A	0.30	0.21
RPHM Reneo Pharmaceuticals	N/A	5.87	5.87

Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
ANVS Annovis Bio	15.83%
GLS Gelesis	16.71%
RPHM Reneo Pharmaceuticals	90.98%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	85.90%
ANVS Annovis Bio	38.30%
GLS Gelesis	11.90%
RPHM Reneo Pharmaceuticals	17.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	2	25.63 million	3.61 million	Not Optionable
ANVS Annovis Bio	6	11.01 million	6.79 million	Optionable
GLS Gelesis	2	73.33 million	64.61 million	Not Optionable
RPHM Reneo Pharmaceuticals	8	33.42 million	27.44 million	Optionable

ANVS, RPHM, ANEB, and GLS Headlines

Source	Headline
	Reneo Pharmaceuticals Inc. thestreet.com - April 14 at 1:20 PM
	Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 0.6% marketbeat.com - April 3 at 2:35 AM
	Sell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price Target markets.businessinsider.com - March 31 at 7:14 PM
	Reneo Pharmaceuticals: Q4 Earnings Insights benzinga.com - March 28 at 4:09 PM
	RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023 investorplace.com - March 28 at 2:01 PM
	Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update finanznachrichten.de - March 28 at 10:52 AM
	Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update globenewswire.com - March 28 at 7:35 AM
	Reneo Pharmaceuticals, Inc. (RPHM) uk.finance.yahoo.com - February 14 at 12:17 AM
	Reneo Pharmaceuticals, Inc. (RPHM) uk.finance.yahoo.com - February 14 at 12:17 AM
	Reneo Pharmaceuticals Inc (RPHM) investing.com - January 30 at 1:28 AM
	Reneo Shares Dive 83% After Drug Fails Trial ocbj.com - January 8 at 8:25 PM
	Sharp increase in RPHM’s short interest leads to surge in days-to-cover ratio knoxdaily.com - January 4 at 12:32 PM
	Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session msn.com - December 27 at 3:51 PM
	Analysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Reneo Pharmaceuticals (RPHM) and Bicycle Therapeutics (BCYC) markets.businessinsider.com - December 19 at 5:49 PM
	Hold Rating on Reneo Pharmaceuticals Following Lead Drug Trial Failure and Strategic Uncertainty markets.businessinsider.com - December 16 at 9:33 AM
	Jefferies Downgrades Reneo Pharmaceuticals (RPHM) msn.com - December 16 at 9:33 AM
	Reneo in trouble after trial failure scotches mavodelpar hopes thepharmaletter.com - December 15 at 12:31 PM
	Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study finance.yahoo.com - December 15 at 12:31 PM
	Reneo Pharmaceuticals just downgraded at BofA, here's why realmoney.thestreet.com - December 15 at 7:30 AM
	5 Analysts Have This to Say About Reneo Pharmaceuticals markets.businessinsider.com - December 15 at 7:30 AM
	Reneo Pharmaceuticals just downgraded at Piper Sandler, here's why realmoney.thestreet.com - December 15 at 1:35 AM
	Reneo Pharmaceuticals just downgraded at Leerink, here's why realmoney.thestreet.com - December 15 at 1:35 AM
	Rare disease company Reneo stops all development bioworld.com - December 14 at 8:35 PM
	Reneo Pharma Hits All-Time Low on Job Cuts, Halted Mavodelpar Development marketwatch.com - December 14 at 3:34 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Anebulo Pharmaceuticals

NASDAQ:ANEB

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Annovis Bio

NYSE:ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Gelesis

NYSE:GLS

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Reneo Pharmaceuticals

NASDAQ:RPHM

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial